TuesdayJan 11, 2022 1:27 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Featured in Latest Episode of Bell2Bell Podcast

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, was featured in the Bell2Bell Podcast, a part of IBN’s (“InvestorBrandNetwork”) sustained effort to provide specialized content distribution via widespread syndication channels. Mydecine’s co-founder, chairman and CEO Josh Bartch joined the latest episode to discuss the company’s business model, highlighting its phased approach to developing improved treatment options for a variety of underserved indications. “Mydecine Innovations Group… is really focused on first- and second-generation novel therapeutics derived from different psychedelic molecules. We’re using those as a…

Continue Reading

TuesdayJan 11, 2022 12:35 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Opens Salt Lake City Clinic

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that its subsidiary, Ketamine Wellness Centers (“KWC”), has officially expanded operations into Utah with the opening of its Salt Lake City location. Acquired by Delic in September 2021, KWC currently operates 11 ketamine infusion treatment clinics across nine states, delivering more than 61,000 treatments to date. “Utah currently experiences one of the highest rates of mental health concerns in the country with lower access to care, and KWC aims to serve this new community of patients struggling with treatment-resistant…

Continue Reading

TuesdayJan 11, 2022 12:28 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures IRB Approval for Feasibility Study Using Kernel’s Quantitative Neuroimaging Technology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that an Institutional Review Board (“IRB”) has approved a company-sponsored feasibility study. The study will use Kernel’s quantitative neuroimaging technology, Kernel Flow, to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. As part of its sponsorship of the feasibility study, Cybin will retain an exclusive interest in any innovations discovered or developed through its independent analysis of the findings. “By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and…

Continue Reading

MondayJan 10, 2022 11:11 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Present at HC Wainwright Bioconnect Virtual Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced details regarding its participation at today's HC Wainwright Bioconnect Virtual Conference. The company’s co-founder and CEO Matt Stang will present on Delic’s expansion strategy and industry outlook heading into 2022 and offer one-on-one meetings with investors. Interested parties should visit https://ibn.fm/eTcfl to register for the event, access Delic's presentation and sign up for a one-on-one meeting. To view the full press release, visit https://ibn.fm/oXYCz Delic Holdings Corp. Delic is a leader in new medicines and treatments for a modern…

Continue Reading

MondayJan 10, 2022 10:09 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Engages JBN Partners LLC, Completes Target-Based Model for AI-Driven Drug Discovery Program

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, has announced its engagement of JBN Partners LLC to increase public awareness of and interest in the company, its management and its products. Under the collaboration, JBN will coordinate certain investor relations and corporate financial public relations with members of the investment community, the financial media and the general public. The services agreement with JBN has a term of six months with a total payment value of $150,000. In addition, the company today announced that it…

Continue Reading

FridayJan 07, 2022 10:57 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes that Adelia Has Reached Milestone Achievement

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its wholly owned subsidiary, Adelia Therapeutics Inc., has a achieved a significant milestone. Specific milestones outlined in the Dec. 4, 2021, contribution agreement define what actions are to be taken when certain milestones are reached. When this specific milestone, identified as Year 2 Q1 (v), is reached,  the agreement calls for 15,611.4 class B common shares to be issued to Adelia shareholders; those shares are exchangeable for common shares in Cybin capital in accordance with parameters defined by the agreement. Adelia is committed to…

Continue Reading

ThursdayJan 06, 2022 2:17 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) Featured on ‘Gamechangers LIVE’

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, was featured in a recent episode of “Gamechangers LIVE.” The podcast series shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. Joshua Bartch, Mydecine’s co-founder, chairman and CEO, joined the broadcast, hosted by executive coach and speaker Sergio Tigera, to discuss his background as an entrepreneur spanning multiple successful ventures across a variety of industries. Bartch…

Continue Reading

WednesdayJan 05, 2022 10:50 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces January 2022 Health Care Conference Schedule

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present next week at the H.C. Wainwright Bioconnect Conference and the Biotech Showcase. The events are slated to be held virtually on Jan. 10-12, 2022. Tryp’s CEO and Chairman Greg McKee will provide an overview of the company and updates on its chronic pain and eating disorder programs. This year, all corporate presentations will be pre-recorded and available on-demand for registered attendees. In addition, replays of the presentations will be available on the Events section…

Continue Reading

WednesdayDec 22, 2021 11:07 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), Maya to Collaborate in Development of Novel DTx Platform

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into a letter of intent (“LOI”) with Maya. The two companies plan to co-develop a novel digital therapeutics (DTx) platform, which would allow Mydecine to enhance treatment effectiveness by pairing the DTx with its existing digital health platform, Mindleap Health, alongside its medication-based treatments to create a trifecta approach. “The technology integration of the two software platforms is aimed at enhancing Mindleap’s medical capabilities to more quickly and efficiently develop a personalized prescription-based digital…

Continue Reading

WednesdayDec 22, 2021 9:54 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Issues 2021 Year-End Summary

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has provided a year-end summary of its major milestones and key catalysts from 2021 that it believes have positioned the company for a transformative 2022. “2021 was an exciting year for Cybin. We expanded our organization from five to more than 55 employees across four countries and have established an operating ecosystem of nearly 50 partners and vendors that have supported more than 90 preclinical studies and numerous patent and investigational new drug filings over the past 12 months,” said Cybin’s CEO Doug Drysdale in…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000